Download PDF
Fortschr Neurol Psychiatr 2000; 68(7): 313-320
DOI: 10.1055/s-2000-11638
ORIGINALARBEIT
Georg Thieme Verlag Stuttgart ·New York

Aussagekraft offener Studien im Vergleich zu kontrollierten Studien in der Prüfung von Neuroleptika

Evaluation of Efficacy of Neuroleptics in Open Versus Double-Blind Trials:F.-G Pajonk, R. Holzbach, D. Naber
  • Klinik für Psychiatrie und Psychotherapie, Universitätskrankenhaus Hamburg-Eppendorf (Geschäftsführender Direktor: Prof. Dr. D. Naber)
Further Information

Publication History

Publication Date:
31 December 2000 (online)

    Permissions and Reprints

Zusammenfassung:

Einleitung: Die Aussagekraft offener Studien zur Wirksamkeit von Neuroleptika wird aus methodischen Gründen oft bezweifelt. Bislang existieren jedoch kaum Studien, die Ergebnisse offener mit denen doppelblinder, kontrollierter Studien vergleichen. Ziel der vorliegenden Untersuchung war der Vergleich von Wirksamkeit und Verträglichkeit in Abhängigkeit von der gewählten Methode, um einen Anhalt für die Wertigkeit der Ergebnisse offener Studien zu gewinnen. Methodik: Nach einer Literaturrecherche wurden nach Anwendung der Einschlusskriterien fünf Neuroleptika identifiziert, für die mindestens je drei offene und doppelblinde, kontrollierte Studien mit ausreichender Fallzahl und Behandlungsdauer vorlagen, aus denen das Behandlungsresultat methodisch ausreichend quantifizierbar und vergleichbar (BPRS-Score, Responserate) zu entnehmen war. Ergebnisse: Es existieren keine Unterschiede hinsichtlich der Reduktion des BPRS-Scores oder der Responserate zwischen offenen und kontrollierten Untersuchungen für alle fünf Neuroleptika. Auch die Wirksamkeit der Präparate untereinander unterschied sich nicht. Diskussion: Doppelblinde, kontrollierte Studien bleiben unverändert unverzichtbar in der Prüfung neuer Substanzen. Die Ergebnisse zur Wirksamkeit von Neuroleptika aus methodisch gut durchgeführten offenen Studien sind aber aussagekräftig und verdienen mehr Beachtung als bisher. Sie können sinnvoll zur Vorbereitung und Durchführung doppelblinder, kontrollierter Studien beitragen.

Objective: Due to methodological reservations, results concerning the efficacy of neuroleptics in open trials are often regarded with doubt. Until now, there are nearly no studies comparing findings of controlled double-blind with those of open trials. Aim of this study was to investigate if results of an open or double-blind approach differ and hereby to gain information about the validity of open trials. Methods: After a literature research, five neuroleptics were identified for which at least 3 open and 3 double-blind trials exist which met the inclusion criteria and from which either the reduction of the BPRS (Brief Psychiatric Rating Scale)-score or the response rate could be determined. Results: There were no differences in the reduction of the BPRS-score or response rate for all 5 neuroleptics between open and double-blind trials. Furthermore, the efficacy of all 5 neuroleptics was comparable. Conclusions: Double-blind controlled studies are essential in the investigation of new compounds. But results of methodologically well performed open studies are valid and deserve more attention. Preceding open trials may help in the design of double-blind studies.

Literatur

  • 1 Angst A, Bobon D, Engel R, Hippius H, Janzen G. et al . Report on the third consensus conference on the methodology of clinical trials with antipsychotic drugs.  Pharmacopsychiatry. 1991;  24 149-152
    PubMedGoogle Scholar
  • 2 Sulzbacher S. Psychotropic medication with children: an evaluation of procedural biases in results of reported studies.  Pediatrics. 1973;  51(3) 513-517
    PubMedGoogle Scholar
  • 3 Kavale K. The efficacy of stimulant drug treatment for hyperactivity: a meta-analysis.  J Learning Disabilities. 1982;  15 280-289
    PubMedGoogle Scholar
  • 4 Klein D. Improvement of phase III psychotropic drug trials by intensive phase II work.  Neuropsychopharmacology. 1991;  4 251-271
    PubMedGoogle Scholar
  • 5 Sprafkin J, Gadow K D. Double-blind versus open evaluations of stimulant drug response in children with attention-deficit hyperactivity disorder.  J of Child and Adolescent Psychopharmacology. 1996;  6(4) 215-228
    PubMedGoogle Scholar
  • 6 Brannen J, McEvoy J P, Wilson W H, Petrie W, Ban T, Berney S, Schaffer J. A double-blind comparison of Bromperidol and Haloperidol in newly admitted schizophrenic patients.  Pharmacopsychiatry. 1981;  14 139-140
    PubMedGoogle Scholar
  • 7 Fleischhacker W, Unterweger B, Barnas C, Stuppäck C, Hinterhuber H. Results of an open phase II study with Zotepine - a new neuroleptic compound.  Pharmacopsychiatry. 1987;  20(Suppl. 1) 64-66
    PubMedGoogle Scholar
  • 8 Sarai K, Okada M. et al . Comparison of efficacy of Zotepine and Thiothixene in schizophrenia in a double-blind study.  Pharmacopsychiatry. 1987;  20(Suppl. 1) 38-46
    PubMedGoogle Scholar
  • 9 Storosum J, Elferink A JA, van Zwieten B J. Schizophrenia: Do we really need placebo-controlled studies.  European Neuropsychopharmacology. 1998;  8 279-286
    CrossrefPubMedGoogle Scholar
  • 10 Pöldinger W, Bures E, Haage H. Clinical study with Bromperidol, a new butyrophenone derivative.  Int Pharmacopsychiat. 1977;  12 20-24
    PubMedGoogle Scholar
  • 11 Haase H, Kaumeier S, Schwarz H, Gundel A, Linde O. et al . Open Study with Bromperidol, a new neuroleptic, for the determination of the neuroleptic treshold and the neuroleptic-therapeutic range.  Pharmacopsychiatry. 1978;  11 81-85
    PubMedGoogle Scholar
  • 12 Hucker H. Bericht über die Anwendung von Bromperidol im offenen Versuch.  Int Pharmacopsychiat. 1978;  13(Suppl. 1) 53-61
    PubMedGoogle Scholar
  • 13 Psaras M, Paterakis P, Manafi T, Zissis N, Lyketsos G. Therapeutic evaluation of Bromperidol in schizophrenia: double-blind comparison with Chlorpromazine in chronic patients and open administration in schizophrenics with acute symptomatology.  Current Therapeutic Research. 1984;  36(6) 189-197
    PubMedGoogle Scholar
  • 14 El-Assra A. Chronic Schizophrenia: a new butyrophenone for possible management. Medical Department, Janssen Pharmaceutical Department Ltd. Unpublished Manuscript. 
  • 15 Bures E, Pöldinger W. Einleitende Worte zum Austausch der Erfahrungen über die klinische Wirkung von Bromperidol.  Int Pharmacopsychiat. 1978;  13(Suppl. 1) 45-52
    PubMedGoogle Scholar
  • 16 Woggon B. Effects and side-effects of bromperidol in comparison with other antipsychotic drugs.  Acta Psychiat Belg. 1978;  78 155-172
    PubMedGoogle Scholar
  • 17 Denijs E. Clinical evaluation of Bromperidol versus Haloperidol in psychotic patients.  Int Pharmacopsychiat. 1980;  15 309-317
    PubMedGoogle Scholar
  • 18 Hitoshi I. A comparison of the clinical effects of Bromperidol, a new butyrophenone derivative, and Haloperidol on schizophrenia using a double-blind technique.  Psychopharmacol Bulletin. 1985;  21(1) 120-122
    PubMedGoogle Scholar
  • 19 Shopsin B, Selzer G. High-Dose Pimozide in acutely ill, newly admitted schizophrenic inpatients.  Current Therapeutic Research. 1977;  21(6) 755-767
    PubMedGoogle Scholar
  • 20 Piyakulmala S, Corbett L, Ahluwalia Y, Berry R, Meltzer H. High dose Pimozide in the treatment of acutely agitated schizophrenia.  Current Therapeutic Research. 1977;  22(4) 453-461
    PubMedGoogle Scholar
  • 21 Feinberg S, Kay S R, Elijovich L R, Fiszbein A, Opler L. Pimozide treatment of the negative schizophrenic syndrome: an open trial.  J Clin Psychiatry. 1988;  49(6) 235-238
    PubMedGoogle Scholar
  • 22 Chouinard G, Annable L. Pimozide in the treatment of newly admitted schizophrenic patients.  Psychopharmacology. 1982;  76 13-19
    CrossrefPubMedGoogle Scholar
  • 23 Haas S, Beckmann H. Pimozide versus Haloperidol in acute schizophrenia. A double blind controlled study.  Pharmacopsychiatry. 1982;  15 70-74
    PubMedGoogle Scholar
  • 24 The Scottish Schizophrenia Research Group . The Scottish first episode schizophrenia study.  British Journal of Psychiatry. 1987;  150 334-338
    PubMedGoogle Scholar
  • 25 Klieser E, Schröder H G, Goncalves J, Strauß W. Über die antipsychotische Wirksamkeit von Remoxiprid, einem selektiven Dopaminantagonisten. Unveröffentlichtes Manuskript. 
  • 26 Lindström L, Besev G, Stening G, Widerlöv E. An open study on Remoxipride, a benzamide derivate, in schizophrenia.  Psychopharmacology. 1985;  86 241-243
    CrossrefPubMedGoogle Scholar
  • 27 McCreadie R, Morrison D, Eccleston D, Gall R, Loudon J, Mitchell M. An open multicentre study of the treatment of florid schizophrenia with Remoxipride.  Acta Psychiatr Scand. 1985;  72 139-143
    PubMedGoogle Scholar
  • 28 Chouinard G. Early phase II clinical trial of Remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity.  J Clin Psychopharmacology. 1987;  7(3) 159-164
    PubMedGoogle Scholar
  • 29 DenBoer J, Verhoeven W MA, Westenberg H GM. Remoxipride in schizophrenia. A preliminary report.  Acta Psychiatr Scand. 1986;  4 409-414
    PubMedGoogle Scholar
  • 30 Hebenstreit G, Laux G, Schubert H, Beckmann H, Amman J, Bunse J, Eikmeier G, Geretsegger C. A double-blind comparative multicentre study of controlled-release Remoxipride, immediate-release Remoxipride and Haloperidol in schizophrenia.  Pharmacopsychiatry. 1991;  24 153-158
    PubMedGoogle Scholar
  • 31 Lapierre Y, Nair N PV, Chouinard G. et al . A controlled dose-ranging study of Remoxipride and Haloperidol in schizophrenia - a Canadian multicentre trial.  Acta Psychiatr Scand. 1990;  82(Suppl. 358) 72-76
    PubMedGoogle Scholar
  • 32 Ahlfors U, Rimon R, Appelberg B. et al . Remoxipride and Haloperidol in schizophrenia: a double-blind multicentre study.  Acta Psychiatr Scand. 1990;  82(Suppl. 358) 99-103
    PubMedGoogle Scholar
  • 33 Andersen J, Korner A, Ostergaard P. et al . A double blind comparative multicentre study of Remoxipride and Haloperidol in schizophrenia.  Acta Psychiatr Scand. 1990;  82(Suppl. 358) 104-107
    PubMedGoogle Scholar
  • 34 DenBoer J, Ravelli D P, Huisman J, Öhrvik J, Verhoeven W, Westenberg H. A double-blind comparative study of Remoxipride and Haloperidol in acute schizophrenia.  Acta Psychiatr Scand. 1990;  82(Suppl. 358) 108-110
    PubMedGoogle Scholar
  • 35 Chouinard G. A placebo-controlled clinical trial of Remoxipride and Chlorpromazine in newly admitted schizophrenic patients with acute exacerbation.  Acta Psychiatr Scand. 1990;  82(Suppl. 358) 111-119
    PubMedGoogle Scholar
  • 36 Deo R. Remoxipride and Haloperidol in the acute phase of schizophrenia: a double-blind comparison.  Acta Psychiatr Scand. 1990;  82(Suppl. 358) 120-124
    PubMedGoogle Scholar
  • 37 Laux G, Klieser E, Schröder H G. et al . A double-blind multicentre study comparing Remoxipride, two and three times daily, with Haloperidol in schizophrenia.  Acta Psychiatr Scand. 1990;  82(Suppl. 358) 125-129
    PubMedGoogle Scholar
  • 38 Lindström L, Wiselgren I M, Struwe G. et al . A double-blind comparative multicentre study of Remoxipride and Haloperidol in schizophrenia.  Acta Psychiatr Scand. 1990;  82(Suppl. 358) 130-135
    PubMedGoogle Scholar
  • 39 Mendlewicz L, deBleeker E, Cosyns P. et al . A double-blind comparative study of Remoxipride and Haloperidol in schizophrenic and schizophreniform disorders.  Acta Psychiatr Scand. 1990;  82(Suppl. 358) 138-141
    PubMedGoogle Scholar
  • 40 Pflug B, Bartels M, Bauer H. et al . A double-blind multicentre study comparing Remoxipride, controlled-release formulation, with Haloperidol in schizophrenia.  Acta Psychiatr Scand. 1990;  82(Suppl. 358) 142-146
    PubMedGoogle Scholar
  • 41 Patris M, Agussol P, Alby J M. et al . A double-blind multicentre comparison of Remoxipride, at two dose levels, and Haloperidol.  Acta Psychiatr Scand. 1990;  82(Suppl. 358) 78-82
    PubMedGoogle Scholar
  • 42 Higashi Y, Momotani Y, Suzuki E, Kaku T. Clinical and EEG studies of Zotepine, a thiepine neuroleptic, on schizophrenic patients.  Pharmacopsychiatry. 1987;  20(Suppl. 1) 8-11
    PubMedGoogle Scholar
  • 43 v Bardeleben U, Benkert O, Holsboer F. Clinical and neuroendocrine effects of Zotepine - a new neuroleptic drug.  Pharmacopsychiatry. 1987;  20(Suppl. 1) 28-34
    PubMedGoogle Scholar
  • 44 Dieterle D, Ackenheil M, Müller-Spahn F, Kapfhammer H. Zotepine, a neuroleptic drug with a bipolar therapeutic profile.  Pharmacopsychiatry. 1987;  20(Suppl. 1) 52-57
    PubMedGoogle Scholar
  • 45 Fleischhacker W, Barnas C, Stuppäck C, Unterweger B, Hinterhuber H. Zotepine in the treatment of negative symptoms in chronic schizophrenia.  Pharmacopsychiatry. 1987;  20(Suppl. 1) 58-60
    PubMedGoogle Scholar
  • 46 Fleischhacker W, Barnas C, Stuppäck C, Sperner-Unterweger B, Miller C, Hinterhuber H. Zotepin versus Haloperidol bei paranoider Schizophrenie: eine Doppelblindstudie.  Fortschr Neurol Psychiat. 1991;  59(Suppl. 1) 10-13
    PubMedGoogle Scholar
  • 47 Dieterle D, Müller-Spahn F, Ackenheil M. Wirksamkeit und Verträglichkeit von Zotepin im Doppelblindvergleich mit Perazin bei schizophrenen Patienten.  Fortschr Neurol Psychiat. 1991;  59(Suppl. 1) 18-22
    PubMedGoogle Scholar
  • 48 Wetzel H, v Bardeleben U, Holsboer F, Benkert O. Zotepin versus Perazin bei Patienten mit paranoider Schizophrenie: eine doppelblind-kontrollierte Wirksamkeitsprüfung.  Fortschr Neurol Psychiat. 1991;  59(Suppl. 1) 23-29
    PubMedGoogle Scholar
  • 49 Sechter D, Caillard V, Cuche H, Deniker P. Open clinical study of cis(Z)-clopenthixol.  Acta Psychiatr Scand. 1981;  64(Suppl. 294) 20-24
    PubMedGoogle Scholar
  • 50 König P, Seifert T, Eberhardt G. Findings with cis-Z-clopenthixol in the treatment of acute mania and schizophrenia.  Pharmacopsychiatry. 1986;  19(6) 424-428
    PubMedGoogle Scholar
  • 51 Bereen F, Harte F B, Maguire J, Singh A. The use of oral Zuclopenthixol in the treatment of functional psychotic illnesses.  Pharmatherapeutica. 1987;  5 62-68
    PubMedGoogle Scholar
  • 52 Gravem A, Engstrand E, Guleng R J. Cis(Z)-clopenthixol and clopenthixol in chronic psychotic patients. A double-blind investigation.  Acta Psychiatr Scand. 1978;  58 384-388
    PubMedGoogle Scholar
  • 53 Gravem A, Bugge A. Cis(Z)-clopenthixol and clopenthixol in the treatment of acute psychoses and exacerbations of chronic psychoses.  Acta Psychiatr Scand. 1981;  64(Suppl. 294) 13-19
    PubMedGoogle Scholar
  • 54 Heikkilae L, Karsten D, Valli K. A double-blind clinical investigation of cis(Z)-clopenthixol and clopenthixol in chronic schizophrenic patients.  Acta Psychiatr Scand. 1981;  64(Suppl. 294) 25-29
    PubMedGoogle Scholar
  • 55 Heikkilae L, Laitinen J, Vartiainen H. Cis(Z)-clopenthixol and Haloperidol in chronic schizophrenic patients - a double-blind clinical multicentre investigation.  Acta Psychiatr Scand. 1981;  64(Suppl. 294) 303
    PubMedGoogle Scholar
  • 56 Woggon B. Cis(Z)-clopenthixol in der Behandlung der akuten Schizophrenien. Kopenhagen; Clopixol Symposium 1983
  • 57 Heikkilae L, Eliander H, Vartiainen H. et al . Zuclopenthixol and Haloperidol in patients with acute psychotic states. A double-blind multicentre study.  Current Medical Research and Opinion. 1992;  12(9) 594-603
    PubMedGoogle Scholar

Dr. Frank-Gerald Pajonk

Klinik für Psychiatrie und Psychotherapie

Universitätskrankenhaus Hamburg-Eppendorf

Martinistr. 52

20246 Hamburg

Email: pajonk@uke.uni-hamburg.de

      >